Pfizer Sings Lyrica's Praises In Beating Earnings Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Company beats recent lowered earnings guidance as a result of strong performance in its human health division as well as faster-than-anticipated cost savings from restructuring program.
You may also be interested in...
Pfizer’s Great Expectations: Sutent, Exubera Forecasts Exceed Those Of Investors
Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.
Pfizer Launches Lyrica Nine Months After First Approval
Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter